Methylene Blue Screening Tool

1) Have you ever had an adverse or allergic reaction to Methylene Blue or blue dye? 	YES OR NO
a) If yes- proceed to consult
2) Have you previously received  Methylene Blue?
a) If Yes, What dose?
3) Are you currently  receiving  Methylene Blue elsewhere?  YES or NO
a) If yes, what dose?
4) Have you ever been diagnosed with any of the following or had any of the following procedures?
a) If yes, proceed to consult
i) Drug induced encephalopathy
ii) Heart operation
iii) Parathyroid Imaging
iv) Lymph node biopsy
v) Vasogenic Shock
5) Have you ever been diagnosed with a G6PD deficiency? 	YES or NO
a) If yes, do not proceed
6) Are you currently taking any of the following?  YES or NO, if yes do not proceed
a) Anti-depressants
i) SSRIs
ii) SNRIs
iii) MAOIs
b) Narcotics-Opioids
c) Buprenorphine, Suboxone, Naloxone
d) Migraine Medications
e) Dapsone
f) Tryptophans
7) Are you currently taking any of the following?  YES or NO, if yes notify prescriber on interaction and proceed with caution
a) Muscle relaxants
b) Amphetamines or stimulants
c) CBD or THC
d) Benzodiazepines- anti anxiety meds
e) Gabapentin or other or nerve medication

8) Are you currently experiencing or have you experienced any of the following?  YES or NO if yes, do not proceed
a) Hemolytic anemia
b) Serotonin syndrome 
9) Are you currently pregnant or breastfeeding?
a) If yes, do not proceed
10) Have you been diagnosed with severe renal insufficiency? 
a) If yes, do not proceed



Initial Consultation
Date Medicine Qty Details Price Comment Additional adviceSmoking Alcohol Depression Medicines side  effects InteractionsLifestyle advice Healthcare professional declarations I confirm that the patient is not contraindicated based on the information provided by the PGD I have explained the potential warnings and side effects of the treatment to the patient, and requested they report them if they occur I have provided the patient with an information leaflet (PIL) for the treatment I am administering, and advised them to read it Healthcare Professional Name Signature Date 
PATIENT CONSENT 
I have received information on the risks and benefits of the erectile dysfunction medicines recommended and fully understand them. I have also had the opportunity to ask questions. I consent to the erectile dysfunction medicines being given at each appointment. 

Patient signature _______________________________   Date      __________

Record of Treatment Provision

New risk assessment form required after 10 consultations. 
For each follow-up consultation Appointment medicine Qty Details Change in medical 
history? Healthcare professional 
Signature Price No.1. Yes Patient Signature Date 

Resources

https://www.micromedexsolutions.com/micromedex2/librarian/CS/9D39EE/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/566AD0/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.GoToDashboard?docId=372710&contentSetId=100&title=Methylene+Blue&servicesTitle=Methylene+Blue&brandName=Provayblue&UserMdxSearchTerm=Provayblue&=null#

https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204630s000lbl.pdf
https://drtoddmaderis.com/methylene-blue-for-lyme-disease-and-bartonella

Hashmi MU, Ahmed R, Mahmoud S, Ahmed K, Bushra NM, Ahmed A, Elwadie B, Madni A, Saad AB, Abdelrahman N. Exploring Methylene Blue and Its Derivatives in
Alzheimer's Treatment: A Comprehensive Review of Randomized Control Trials. Cureus. 2023 Oct 9;15(10):e46732. doi: 10.7759/cureus.46732. PMID: 38022191;
PMCID: PMC10631450.

Ou G, Che J, Dong J, Deng Y, Jiang X, Sun Y, He Z, Chen W, Zhang J. Methylene blue targets PHD3 expression in murine microglia to mitigate
lipopolysaccharide-induced neuroinflammation and neurocognitive impairments. Int Immunopharmacol. 2023 Jul;120:110349. doi:
10.1016/j.intimp.2023.110349. Epub 2023 May 22. PMID: 37210913.

Azam S, Haque ME, Balakrishnan R, Kim IS, Choi DK. The Ageing Brain: Molecular and Cellular Basis of Neurodegeneration. Front Cell Dev Biol. 2021 Aug
13;9:683459. doi: 10.3389/fcell.2021.683459. PMID: 34485280; PMCID: PMC8414981.

Stelmashook EV, Voronkov DN, Stavrovskaya AV, Novikova SV, Yamshikova NG, Olshanskij AS, Guschina AS, Shedenkova MO, Genrikhs EE, Isaev NK. Neuroprotective
effects of methylene blue in streptozotocin-induced model of Alzheimer's disease. Brain Res. 2023 Apr 15;1805:148290. doi: 10.1016/j.brainres.2023.148290. Epub 2023
Feb 18. PMID: 36804486.

Soliman M, Salah M, Fadel M, Nasr M, El-Azab H. Contrasting the efficacy of pulsed dye laser and photodynamic methylene blue nanoemulgel therapy in
treating acne vulgaris. Arch Dermatol Res. 2021 Apr;313(3):173-180. doi: 10.1007/s00403-020-02093-y. Epub 2020 May 24. PMID: 32449013.
- WOUND

Gao Y, Jiang Z, Xu B, Mo R, Li S, Jiang Y, Zhao D, Cao W, Chen B, Tian M, Tan Q.
Evaluation of topical methylene blue nanoemulsion for wound healing in diabetic mice.
Pharm Biol. 2023 Dec;61(1):1462-1473. doi: 10.1080/13880209.2023.2254341. PMID:
37691404; PMCID: PMC10496548.

Roldan CJ, Rosenthal DI, Koyyalagunta D, Feng L, Warner K. Methylene Blue for the Treatment of Radiation-Induced Oral Mucositis during Head and Neck Cancer
Treatment: An Uncontrolled Cohort. Cancers (Basel). 2023 Aug 7;15(15):3994. doi: 10.3390/cancers15153994. PMID: 37568810; PMCID: PMC10417523.

Roldan CJ, Chung M, Feng L, Bruera E. Methylene Blue for the Treatment of Intractable Pain From Oral Mucositis Related to Cancer Treatment: An Uncontrolled
Cohort. J Natl Compr Canc Netw. 2021 Jan 4;19(5):521-527. doi: 10.6004/jnccn.2020.7651. PMID: 33395626.

Schalch TO, Piatto ÉT, Simão DS, Bussadori SK, Motta LJ, Pavani C, Horliana ACRT. Pericoronitis treatment with antimicrobial photodynamic therapy using a new
formula of methylene blue: A case report. Photodiagnosis Photodyn Ther. 2023 Jun;42:103331. doi: 10.1016/j.pdpdt.2023.103331. Epub 2023 Feb 11. PMID: 36781007.

Neto FS, Hachul H, Pereira MA, Filho CI. Efficacy of methenamine with methylthioninium in the treatment of dysuria: a randomized clinical study. Int Urogynecol J. 2023
Dec;34(12):3051-3058. doi: 10.1007/s00192-023-05669-0. Epub 2023 Oct 18. PMID: 37851092; PMCID: PMC10756887.




